熱門詞： 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥
熱門詞： 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥
Neurocrine 美國Neurocrine Biosciences?
Neurocrine Biosciences, Inc of San Diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs.
The Company's research and development efforts are focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders.
Pipeline Highlights
The Company has a rich and diversified pipeline with compounds in all phases of clinical development.
Neurocrine's Pipeline
GnRH Antagonists
Neurocrine is currently conducting a Phase IIb study in which 252 patients with endometriosis will be treated over a 6-month period. This multi-center, randomized, double-blind, study includes three treatment groups, with two doses of NBI-56418, 150 mg once a day and 75 mg twice daily, and an active comparator. This study is designed primarily to assess the impact of longer term treatment on bone mineral density as measured by radiological scan at the conclusion of dosing and at 6-months and 12-months post-treatment. The 6-month results, together with data from other Phase II studies, will be the basis for securing agreement on a registration plan with the FDA.
Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in Men’s and Women’s Health.
Corticotropin Releasing Factor (CRF1) Receptor Antagonists
The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and IBS. GSK has completed the first Phase II "proof of concept" clinical trial with a lead CRF1 receptor antagonist compound, 876008, for SocAD and has completed recruiting for a Phase II "proof of concept" clinical trial in IBS.
Urocortin 2 for congestive heart failure (CHF):
Neurocrine licensed urocortin 2 to further expand the Company’s franchise in corticotropin-releasing factor (CRF) research.
Research Programs
Neurocrine’s Research Group continues to advance novel small molecule compounds into clinical development. Neurocrine scientists are focusing on developing small molecule antagonists against G-protein coupled receptors. Our scientists possess the skills and experience necessary to bring compounds from basic research concepts to drug candidate stage. Neurocrine utilizes advanced technologies to enhance its drug discovery capabilities and to accelerate the drug development process. Working together, Neurocrine's chemists, pharmacologists and biologists strive to create new solutions to unmet medical problems necessary to deliver one new drug candidate every 12 months.
Neurocrine Biosciences Corporate Information
The Company’s common stock is traded on the Nasdaq Global Select Market System under the symbol “NBIX”
?
知識產(chǎn)權(quán)侵權(quán)投訴：不生產(chǎn)任何產(chǎn)品所有產(chǎn)品均來自產(chǎn)品的生產(chǎn)廠商、代理商、經(jīng)銷商，如有侵權(quán)請聯(lián)系：400-006-7520 ，我們會在第一時間處理
本網(wǎng)站所有產(chǎn)品與藥品無關(guān)
滬公網(wǎng)安備31011502016460號
